XML 54 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
Condensed Consolidated Statements of Cash Flows (USD $)
 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Operating activities:      
Net loss $ (37,998,000)us-gaap_NetIncomeLoss $ (41,948,000)us-gaap_NetIncomeLoss $ (23,509,000)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 310,000us-gaap_DepreciationDepletionAndAmortization 298,000us-gaap_DepreciationDepletionAndAmortization 193,000us-gaap_DepreciationDepletionAndAmortization
Amortization of Intangible Assets     111,000us-gaap_AmortizationOfIntangibleAssets
Noncash interest expense 217,000us-gaap_AmortizationOfFinancingCostsAndDiscounts 173,000us-gaap_AmortizationOfFinancingCostsAndDiscounts 22,000us-gaap_AmortizationOfFinancingCostsAndDiscounts
Financing derivative 89,000us-gaap_IncreaseDecreaseInDerivativeLiabilities    
Amortization of premium on marketable securities 495,000us-gaap_InvestmentIncomeAmortizationOfPremium 416,000us-gaap_InvestmentIncomeAmortizationOfPremium 237,000us-gaap_InvestmentIncomeAmortizationOfPremium
Stock based compensation expense 2,013,000us-gaap_ShareBasedCompensation 1,440,000us-gaap_ShareBasedCompensation 821,000us-gaap_ShareBasedCompensation
Loss (gain) on disposal of fixed assets     (146,000)us-gaap_GainLossOnDispositionOfAssets
Change in fair value of preferred stock warrant liabilities     (39,000)us-gaap_FairValueAdjustmentOfWarrants
Changes in operating assets and liabilities:      
Contract receivables 44,000us-gaap_IncreaseDecreaseInAccountsReceivable 43,000us-gaap_IncreaseDecreaseInAccountsReceivable 90,000us-gaap_IncreaseDecreaseInAccountsReceivable
Prepaid expenses and other assets (257,000)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (435,000)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (291,000)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Accounts payable (1,375,000)us-gaap_IncreaseDecreaseInAccountsPayable 1,223,000us-gaap_IncreaseDecreaseInAccountsPayable 2,007,000us-gaap_IncreaseDecreaseInAccountsPayable
Accrued compensation 309,000us-gaap_IncreaseDecreaseInAccruedSalaries 463,000us-gaap_IncreaseDecreaseInAccruedSalaries (205,000)us-gaap_IncreaseDecreaseInAccruedSalaries
Deferred revenue     (5,630,000)us-gaap_IncreaseDecreaseInDeferredRevenue
Accrued research and clinical liabilities 161,000kbio_IncreaseDecreaseInAccruedClinicalAndResearch (229,000)kbio_IncreaseDecreaseInAccruedClinicalAndResearch 2,459,000kbio_IncreaseDecreaseInAccruedClinicalAndResearch
Other liabilities (114,000)us-gaap_IncreaseDecreaseInOtherOperatingLiabilities (256,000)us-gaap_IncreaseDecreaseInOtherOperatingLiabilities 27,000us-gaap_IncreaseDecreaseInOtherOperatingLiabilities
Deferred rent 167,000kbio_IncreaseDecreaseInDeferredRent (3,000)kbio_IncreaseDecreaseInDeferredRent (53,000)kbio_IncreaseDecreaseInDeferredRent
Net cash used in operating activities (35,939,000)us-gaap_NetCashProvidedByUsedInOperatingActivities (38,815,000)us-gaap_NetCashProvidedByUsedInOperatingActivities (23,906,000)us-gaap_NetCashProvidedByUsedInOperatingActivities
Investing activities:      
Purchase of marketable securities (54,163,000)us-gaap_PaymentsToAcquireInvestments (46,852,000)us-gaap_PaymentsToAcquireInvestments (25,507,000)us-gaap_PaymentsToAcquireInvestments
Proceeds from maturities of marketable securities 46,379,000us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments 26,035,000us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments 30,432,000us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
Proceeds from sales of marketable securities   7,241,000us-gaap_ProceedsFromSaleOfShortTermInvestments  
Purchases of property and equipment (448,000)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (344,000)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (20,000)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Proceeds from sale of property and equipment     170,000us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment
Change in restricted cash 12,000us-gaap_IncreaseDecreaseInRestrictedCash    
Net cash (used in) provided by investing activities (8,220,000)us-gaap_NetCashProvidedByUsedInInvestingActivities (13,920,000)us-gaap_NetCashProvidedByUsedInInvestingActivities 5,075,000us-gaap_NetCashProvidedByUsedInInvestingActivities
Financing activities:      
Proceeds from issuance of common stock in initial public offering, net of underwriting costs   65,100,000us-gaap_ProceedsFromIssuanceInitialPublicOffering  
Proceeds from the sale of common stock, net of underwriting costs   32,430,000us-gaap_ProceedsFromIssuanceOfCommonStock  
Payments of offering related costs   (1,686,000)us-gaap_PaymentsOfStockIssuanceCosts (2,329,000)us-gaap_PaymentsOfStockIssuanceCosts
Proceeds from issuance of notes payable 5,000,000us-gaap_ProceedsFromIssuanceOfLongTermDebt   9,840,000us-gaap_ProceedsFromIssuanceOfLongTermDebt
Principal payments under notes payable (4,211,000)us-gaap_ProceedsFromRepaymentsOfDebt    
Proceeds from the exercise of stock options 73,000us-gaap_ProceedsFromStockOptionsExercised 164,000us-gaap_ProceedsFromStockOptionsExercised 84,000us-gaap_ProceedsFromStockOptionsExercised
Proceeds from issuances of Series E preferred stock, net     18,845,000us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
Net cash provided by financing activities 862,000us-gaap_NetCashProvidedByUsedInFinancingActivities 96,008,000us-gaap_NetCashProvidedByUsedInFinancingActivities 26,440,000us-gaap_NetCashProvidedByUsedInFinancingActivities
Net (decrease) increase in cash and cash equivalents (43,297,000)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 43,273,000us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 7,609,000us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents, beginning of period 54,220,000us-gaap_CashAndCashEquivalentsAtCarryingValue 10,947,000us-gaap_CashAndCashEquivalentsAtCarryingValue 3,338,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents, end of period 10,923,000us-gaap_CashAndCashEquivalentsAtCarryingValue 54,220,000us-gaap_CashAndCashEquivalentsAtCarryingValue 10,947,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental cash flow disclosure:      
Cash paid for interest 990,000us-gaap_InterestPaid 890,000us-gaap_InterestPaid 109,000us-gaap_InterestPaid
Supplemental disclosure of noncash financing activities:      
Conversion of preferred stock to common stock and additional paid-in capital   102,023,000us-gaap_ConversionOfStockAmountConverted1  
Reclassification of preferred stock warrants liability to additional paid-in capital 157,000kbio_ReclassificationOfConvertiblePreferredStockWarrantLiabilityToAdditionalPaidInCapital 157,000kbio_ReclassificationOfConvertiblePreferredStockWarrantLiabilityToAdditionalPaidInCapital  
Issuance of common stock warrants in connection with a loan amendment   130,000us-gaap_ConversionOfStockAmountIssued1  
Issuance of preferred stock warrant issued with note payable     $ 79,000kbio_WarrantIssuedInConnectionWithConvertibleNotes